M/s VENUS REMEDIES LTD. was incorporated as a private limited company
on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt
Ltd, and subsequently converted into a public limited company, vide
fresh certificate of incorporation dated 19th Sept. 1994 and the name
converted as Venus Remedies Ltd under the Companies Act, issued by
the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh
at Jalandhar. The company started its production in the year 1991
Intravenous/Intramuscular (IV/IM) injectable forms at its running
unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala
(Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops
during the year 1994. During the same year, the company also
expanded its existing
capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and
that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section
and vial section respectively. And, during 1994, the company has also
certified as WHO-GMP (Good practices in manufacturing and quality
control) as specified by WHO, Geneva by the State Drug Controller of
MAIN OBJECTS OF THE COMPANY
The main objects of the company as set out in its Memorandum of
Association are :
1. To manufacture, import, export of intravenous transfusion fluids
and formations such as dextrose, dextrose with sodium chloride,
normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol
etc. in various concentrations, intravenous solution for dialysis
ACD Sterile bottles for blood collections, pharmaceutical parenteral
preparations like Aminophylline, Adernaline, Water for injection,
Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam,
Oxyphenbutazone & other injectables.
2. To carry on the business of deriving, formulating, purchasing,
producing manufacturing, preparing, processing, mising, compounding,
refining, marketing, distributing, selling and trading in
pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs
of all kinds, specifications and descriptions, and to do so
respect of all kinds of analgesics and antipyretics.
3. To carry on the business of purchasing, producing manufacturing,
preparing, processing, mixing, compounding, refining, marketing,
distributing, selling and trading in all classes and kinds of raw
material ingredients, mixtures, compounds and derivatives connected
intermediate in or associated with the manufacture production and
sale of pharmaceuticals, chemicals medicines and drugs.
4. To carry on the business of vialling, bottling, packing. repacking
and processing of capsules, syrups, tablets, injectables, aerosoles
and ointment, bulk drugs and chemicals.
-Venus Remedies successfully launches its Brand Ronem
-Venus Remedies announces Strategic Marketing tie up with M/S Cadila
- M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up
with Venus Remedies Ltd.
-Delist equity shares from Delhi, Jaipur & Ahmedabad Stock
-Venus Remedies has entered into Strategic Marketing Agreement with
Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd,
Darmstadt, Germany, for its Oncology range of products.
-Venus Remedies sets up a wholly owned subsidiary in Germany
-Venus Remedies Ltd has informed that a Company has been granted
three prestigious ISO certifications
-Venus Remedies in-licenses product Technology from USA
-Venus Remedies Ltd has signed an agreement with M/s. Pharma Match
R&D B.V. a limited Company based at Amsterdam, Netherlands for
jointly preparing, registering and marketing an EU E-CTD Dossier for
a latest generation Carbapenem Injectible.
-Venus facilities Accredited with European GMP Certification.
-Venus Remedies Ltd has informed that the Company's manufacturing
facilities have been approved by the G.F.T.O of Syria for
manufacturing and exporting its products to Syria.
-Venus Remedies - European AMP Accreditation for Venus Oncology
-Venus Remedies Ltd has informed that the Company has successfully
launched its fourth Research Product, a Fixed Dose Combination of
Cephalosporin with aminoglycoside under the
Brand name TOBRACEF in Domestic Market for the first time globally.
-Venus Remedies - Product Patent for TOBRACEF granted in South
-Venus Bags Another Product Patent from South Africa for POTENTOX.
--Registered Office of the Company has been shifted from SCO 39,
Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC
Manimajra, Chandigarh - 160 101.
-Venus Remedies Ltd, a fast-growing pharmaceutical company in the
country, has launched MEBATIC, a unique antibiotic combination in
infusion form to cure severe gastro intestinal (GI) infections.
-Venus Remedies receives GMP Certification from Botswana.
-Venus Remedies ties up with IMTECH and Panjab Univ to develop
Typhoid detection kits.
-The Company has received approval from the Reserve Bank of India for
rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15,
-Venus Remedies research Blockbuster Sulbactomax gets European Union
-Venus Remedies Anti-Cancer drug GEMCITABINE gets UK MHRA approval.
-Sulbactomax patent from Mexico strengthens Venus Remedies' presence
in Latin America.
-Venus Remedies successfully completes Phase I & II Clinical Trials
of TUMATREK (VRP162O), cancer detection molecule.
-Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed
Martin India Innovation Growth Program 2011.
-Venus launches its patented research product ACHNIL” in India.
-Venus Remedies wins India Manufacturing Excellence Award 2011.
-VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year
-VenusRemedis - Innovative Solution for alleviating cancer.
-Venus Remedies introduces Ready-to-Use Single Vial Taxedol in
-Venus Remedies Limited introduced TROIS that is a research based,
patent protected topical nano-emulsion product in India
-The Company has won Manufacturing Award for its world class
manufacturing and operational excellence at the Industry 2.0
Manufacturing Innovation Conclave 2012.
-Venus wins Patent award in Silver Category.
-Venus Remedies launches Elores - CSE 1034, a US Patent projected
product in India.
-Venus Remedies signs MoU for Elores with South African
-Venus Remedies takes its flagship product, Elores into Latin
-Venus launches its first OTC product Ezenus.
-Venus sign Exclusive Marketing Rights deal for its novel Antibiotic
Ajuvant Entity to South Africas second largest Pharmaceutical Company
-Venus Remedies MEROPENEM receives market authorization in Mexico.
-Venus Remedies Ltd has informed regarding ELORES awarded Gold Medal
for being the best Innovation of 2013
-Venus wins Innovative 100 Award for ELORES.
-Venus bags UBM India Pharma Award for Elores.
-Venus ties up with Mylan for marketing meropenem in three European
- VMRC Drug VRP008 to Fight MULTI-DRUG Resistant Bacteria Receives
-Venus Receives Market Authorization for Meropenem from SWITZERLAND